These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37167705)

  • 21. Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action.
    Nishida H; Arikawa Y; Hirase K; Imaeda T; Inatomi N; Hori Y; Matsukawa J; Fujioka Y; Hamada T; Iida M; Nishitani M; Imanishi A; Fukui H; Itoh F; Kajino M
    Bioorg Med Chem; 2017 Jul; 25(13):3298-3314. PubMed ID: 28442261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
    Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural flavonoid myricetin inhibits gastric H
    Miyazaki Y; Ichimura A; Sato S; Fujii T; Oishi S; Sakai H; Takeshima H
    Eur J Pharmacol; 2018 Feb; 820():217-221. PubMed ID: 29274333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump.
    Odiase E; Zhang X; Chang Y; Nelson M; Balaji U; Gu J; Zhang Q; Pan Z; Spechler SJ; Souza RF
    Gastroenterology; 2021 May; 160(6):2072-2088.e6. PubMed ID: 33581123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soraprazan: setting new standards in inhibition of gastric acid secretion.
    Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H
    Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of 4-(phenylamino)quinoline-3-carboxamides as a novel class of gastric H+/K+-ATPase inhibitors.
    Uchida M; Otsubo K; Matsubara J; Ohtani T; Morita S; Yamasaki K
    Chem Pharm Bull (Tokyo); 1995 Apr; 43(4):693-8. PubMed ID: 7600619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases.
    Ku JM; Cho JH; Kim K; Kim JY; Kim JY; Kim J; Cha H; Cheon B
    Pharmacol Res Perspect; 2023 Jun; 11(3):e01090. PubMed ID: 37147903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors?
    Kinoshita Y; Ishimura N; Ishihara S
    Am J Gastroenterol; 2018 Oct; 113(10):1417-1419. PubMed ID: 29955116
    [No Abstract]   [Full Text] [Related]  

  • 31. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers.
    Nishida H; Hasuoka A; Arikawa Y; Kurasawa O; Hirase K; Inatomi N; Hori Y; Sato F; Tarui N; Imanishi A; Kondo M; Takagi T; Kajino M
    Bioorg Med Chem; 2012 Jun; 20(12):3925-38. PubMed ID: 22579619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of potassium in acid secretion.
    Geibel JP
    World J Gastroenterol; 2005 Sep; 11(34):5259-65. PubMed ID: 16149129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of gastric H
    Fujii T; Sugimoto K; Noda T; Shimizu T; Matsuya Y; Sakai H
    Biochem Biophys Res Commun; 2021 Aug; 567():177-182. PubMed ID: 34166915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoration of acid secretion following treatment with proton pump inhibitors.
    Shin JM; Sachs G
    Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuing development of acid pump inhibitors: site of action of pantoprazole.
    Shin JM; Besancon M; Prinz C; Simon A; Sachs G
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of H+/K+ ATPase in the gastroprotective effect of Baccharis illinita DC.
    Freitas CS; Baggio CH; Finau J; Anginoni M; Pizzolatti MG; Santos AR; Marques MC
    J Pharm Pharmacol; 2008 Aug; 60(8):1105-10. PubMed ID: 18644203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastric secretion.
    Schubert ML
    Curr Opin Gastroenterol; 2011 Oct; 27(6):536-42. PubMed ID: 21897223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
    Tomiyama Y; Morii M; Takeguchi N
    Biochem Pharmacol; 1994 Nov; 48(11):2049-55. PubMed ID: 7802694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel approaches to the pharmacological blockade of gastric acid secretion.
    Parsons ME; Keeling DJ
    Expert Opin Investig Drugs; 2005 Apr; 14(4):411-21. PubMed ID: 15882117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.